Consulta las presentaciones y los estudios destacados en ESMO 2026.
Pósteres Roche
Fecha y horario no indicados
Outcomes by baseline tumor burden using the 6-and-12 scores and the up-to-seven criteria in TALENTACE: A phase 3, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo/Bev) or on demand TACE alone in patients (pts) with systemically untreated, unresectable hepatocellular carcinoma (uHCC)
Molécula / tratamiento
Atezo + Beva
Autoría
Sadahisa Ogasawara
Sesión / ubicación
1700eP · e-poster
Fecha y horario no indicados
IMbrave150. Exploratory analysis. Characterization of Patients who are Progression-Free at 6 Months with atezolizumab plus bevacizumab or sorafenib: Post-Hoc Analysis of the IMbrave150 trial. Hepatocellular
Molécula / tratamiento
Atezo + Beva
Autoría
Angela Lamarca
Sesión / ubicación
1695eP · e-poster
Estudios independientes financiados por Roche (IIS)
Adjuvant atezolizumab in patients with MSI-high/MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy –the Phase II ANTONIO-study
A021502 ATOMIC: Comparing presentation and outcomes in patients (pts) with stage III d-MMR early-onset colon cancer (EOCC) and average-onset colon cancer (AOCC)
